Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Accenture
Fuji
Medtronic
Farmers Insurance
UBS
Mallinckrodt
US Army
Dow

Generated: June 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,680,124

« Back to Dashboard

Which drugs does patent 8,680,124 protect, and when does it expire?

Patent 8,680,124 protects STIVARGA and is included in one NDA.

This patent has six patent family members in five countries.
Summary for Patent: 8,680,124
Title:Treatment of cancers with acquired resistance to kit inhibitors
Abstract: The present invention provides compositions and uses thereof for treating cancers which have acquired resistance to a KIT inhibitor by administering effective amounts of DAST (4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyrid- ine-2-carboxylic acid methylamide).
Inventor(s): Wilhelm; Scott (Morristown, NJ), Gedrich; Richard W. (Louisville, CO)
Assignee: Bayer Healthcare LLC (Whippany, NJ)
Application Number:12/523,652
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,680,124
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,680,124

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bayer Hlthcare STIVARGA regorafenib TABLET;ORAL 203085-001 Sep 27, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST), INCLUDING BUT NOT LIMITED TO PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND PATIENTS WITH GIST HAVING RESISTANCE TO A KIT TYROSINE KINASE INHIBITOR ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,680,124

PCT Information
PCT FiledJanuary 18, 2008PCT Application Number:PCT/US2008/051406
PCT Publication Date:July 24, 2008PCT Publication Number: WO2008/089389

International Family Members for US Patent 8,680,124

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2675980 ➤ Try a Free Trial
European Patent Office 2129376 ➤ Try a Free Trial
Spain 2429107 ➤ Try a Free Trial
Japan 2010516693 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Chubb
Cantor Fitzgerald
Harvard Business School
Citi
US Department of Justice
Covington
Healthtrust
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.